sub:assertion { d:DB05463v:identifier "DB05463" ; v:namespace "drugbank" ; v:uri "http://bio2rdf.org/drugbank:DB05463" ; v:x-identifiers.org <http://identifiers.org/drugbank/DB05463> ; dv:drugbank-id "DB05463" ; dv:x-cas <http://bio2rdf.org/cas:> ; dct:description "ISS 1018 is a short, synthetic, unmethylated CpG oligodeoxynucleotide (CpG ODN) with immunostimulatory activity. ISS 1018 signals through Toll-like receptor 9 (TLR9) to induce the production of immunoglobulin by B cells and interferon (IFN) -alpha, IFN-beta, interleukin-12 (IL-12), and tumor necrosis factor - alpha (TNF-alpha) by plasmacytoid dendritic cells (pDC). ISS 1018 CpG ODN promotes antigen presentation and co-stimulatory molecule expression. ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults. It is also being investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma."@en ; dct:identifier "drugbank:DB05463" ; dct:title "ISS-1018"@en ; adv:Drug ; rdfs:label "ISS-1018 [drugbank:DB05463]"@en ; rdfs:seeAlso <http://www.drugbank.ca/drugs/DB05463> . }